Levetiracetam Aurovitas

Levetiracetam, the active ingredient in Levetiracetam Aurovitas, is an anticonvulsant presented as an intravenous solution for intravenous use. It is used as adjunctive therapy for partial‑onset seizures and generalized tonic‑clonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic medication indicated for seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing therapy. Generalized tonic‑clonic seizures: lowers seizure occurrence as an adjunctive treatment. Adjunctive therapy for epilepsy: improves overall seizure control in patients requiring additional medication.

Levetiracetam is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Blood dyscrasias such as neutropenia - Severe skin rash - Respiratory depression (rare)

Levetiracetam requires careful monitoring in several clinical situations.

Renal impairment: adjust dose according to renal function. Hepatic impairment: monitor liver enzymes and consider dose modification. Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Concomitant CNS depressants: observe for enhanced sedation or respiratory effects. Psychiatric history: watch for mood changes, depression, or suicidal ideation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam may interact with other medicines, necessitating vigilance.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Phenobarbital: can reduce levetiracetam levels. - Phenytoin: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Alcohol: may increase central nervous system depression. - Other antiepileptics (e.g., valproate): may require therapeutic drug monitoring.